MagicRNA In Vivo CAR T Lupus Data 2025 Hits New England Journal of Medicine
- MagicRNA announced the publication of clinical data for HN2301 in The New England Journal of Medicine, marking it as the world's first mRNA-LNP based in vivo CAR T candidate in autoimmune disease.
- At a dosage of 4 mg per infusion, 60% of CD8+ CAR+ T-cells were reprogrammed within six hours, leading to B cell depletion lasting 7-10 days.
- MagicRNA plans to continue dose-escalation studies to further evaluate HN2301's potential for immune reset and long-term remission based on positive results.
- No severe adverse events were reported during the treatment, with patients not experiencing grade ≥3 CRS or neurotoxic effects.
39 Articles
39 Articles
Bennington Banner
MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine.
First-ever clinical data supporting safety and efficacy of in vivo CAR-T Therapy in refractory systemic lupus erythematosus (SLE) patients.Data shows low dose of HN2301 reprogrammed up to 60% of CD8+ CAR+ T-cells in the peripheral blood of patients, resulting in…
MagicRNA In Vivo CAR T Lupus Data 2025 Hits New England Journal of Medicine
SHENZHEN, China, Sept. 18, 2025 /PRNewswire/ -- MagicRNA, a clinical-stage biotechnology company pioneering in vivo CAR T-cell therapies, today announced the publication of the world's first clinical data of an mRNA-lipid nanoparticle (mRNA-LNP) based in vivo CAR T candidate, HN2301, in The New England Journal of Medicine. The study, titled "In vivo CD19-CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus", represents the first-ever d…
Coverage Details
Bias Distribution
- 62% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
